About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Portland | 10,048 Studies Near You | Clareo Health

Clinical Trials LocationsPortland

Clinical Trials in Portland

Discover 10,048 clinical trials near Portland, Oregon. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9581-9600 of 10,048 trials

COMPLETEDPhase 2< 1 mile

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

NCT00077974

To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma

Carcinoma, Renal Cell

Pfizer106 participantsStarted Feb 2004

Duarte, California, United States • Pasadena, California, United States • San Francisco, California, United States +12 more locations

COMPLETEDPhase 3< 1 mile

Effects of Antidepressants on Sexual Functioning

NCT00051259

The purpose of this trial is to study the effects of two depression medications on sexual functioning.

Major Depressive Disorder (MDD)

GlaxoSmithKline420 participantsStarted Jan 2003

Berkeley, California, United States • Beverly Hills, California, United States • La Mesa, California, United States +20 more locations

Find Trials by Condition in Portland

Breast Cancerin Portland Lung Cancerin Portland Prostate Cancerin Portland Colorectal Cancerin Portland Melanomain Portland Leukemiain Portland Lymphomain Portland Pancreatic Cancerin Portland Ovarian Cancerin Portland Brain Cancerin Portland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

NCT00053638

This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.

GlaxoSmithKline345 participantsStarted Feb 2003

Phoenix, Arizona, United States • Fountain Valley, California, United States • Los Angeles, California, United States +55 more locations

COMPLETEDPhase 3< 1 mile

A Randomized Clinical Trial of Cognitive-Behavioral Treatment for Post-Traumatic Stress Disorders in Women

NCT00032617

The purpose of the proposed DVA cooperative study is to evaluate the efficacy of exposure therapy for treating PTSD and associated problems in female veterans and active duty military personnel. We propose to compare exposure therapy, Prolonged Exposure, with a comparison therapy that focuses on current problems, Present Centered Therapy. The study is a randomized clinical trial involving 384 female veterans and active duty personnel in 11 VA medical centers and 1 DoD medical center. All subjects, even self-referrals, will enter the study through referrals by mental health clinicians at the participating sites. Following informed consent, subjects will be screened for inclusion and exclusion diagnoses. If they meet these criteria and agree to participate, they will be randomly assigned to one of the two treatments, which will occur weekly for 10 weeks. Subjects will be assessed before treatment, immediately following treatment, and 3 and 6 months after the end of treatment. The primary outcome is PTSD severity. Secondary outcomes are anxiety and depression. Exploratory outcomes include associated features of PTSD, such as dissociation and substance abuse; psychosocial functioning, quality of life, physical health, satisfaction with treatment, and service utilization. Both treatments will be described in detail in a treatment manual and monitored intensively to ensure that they are administered correctly.

Stress Disorders, Post-Traumatic

US Department of Veterans Affairs284 participantsStarted Aug 2002

Denver, Colorado, United States • Bay Pines, Florida, United States • Decatur, Georgia, United States +10 more locations

COMPLETEDPhase 3< 1 mile

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744

The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.

Chronic Obstructive Pulmonary Disease

AstraZeneca1,200 participantsStarted Jan 2007

Jasper, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +137 more locations

COMPLETEDPhase 2/3< 1 mile

Dose Ranging Study With LT, Monotherapy, PPAR

NCT00240383

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Diabetes Mellitus II

Bristol-Myers Squibb1,260 participantsStarted May 2002

Anniston, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +269 more locations

COMPLETEDPhase 3< 1 mile

PPAR-COMBO With Sulfonylurea

NCT00162175

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.

Metabolics Diabetes Nos

Bristol-Myers Squibb534 participantsStarted Jul 2003

Anniston, Alabama, United States • Hoover, Alabama, United States • Huntsville, Alabama, United States +146 more locations

COMPLETEDPhase 3< 1 mile

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030

The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.

Diabetes Mellitus, Type 2

Bristol-Myers Squibb1,752 participantsStarted Feb 2004

Birmingham, Alabama, United States • Mesa, Arizona, United States • Phoenix, Arizona, United States +203 more locations

COMPLETEDPhase 18.6 miles

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

NCT00327327

AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.

Pancreatic Adenocarcinoma

AmpliMed Corporation105 participantsStarted Feb 2004

Tucson, Arizona, United States • Ocoee, Florida, United States • Indianapolis, Indiana, United States +6 more locations

COMPLETEDPhase 243 miles

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

Anxiety Disorders

AstraZeneca369 participantsStarted Dec 2008

Mesa, Arizona, United States • Little Rock, Arkansas, United States • Carson, California, United States +48 more locations

COMPLETEDPhase 4121 miles

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508

Evaluate the effect of VESIcare® on symptom bother for subjects with OAB

Urinary Bladder, Overactive

Astellas Pharma Inc768 participantsStarted Aug 2007

Montgomery, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +56 more locations

COMPLETEDPhase 1145 miles

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

NCT00006480

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy and gene therapy in treating children who have recurrent or refractory neuroblastoma.

Fred Hutchinson Cancer CenterStarted May 2000

Duarte, California, United States • Seattle, Washington, United States

COMPLETEDPhase 1/2145 miles

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004158

RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy using holmium Ho 166 DOTMP plus melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.

Multiple Myeloma and Plasma Cell Neoplasm

Fred Hutchinson Cancer CenterStarted Jun 1999

Miami, Florida, United States • Houston, Texas, United States • Seattle, Washington, United States +1 more locations

COMPLETEDNA145 miles

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

NCT00049465

RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer. PURPOSE: Randomized clinical trial to compare the effectiveness of standard follow-up care with extended follow-up care in treating patients who have undergone stem cell transplantation for cancer.

Fred Hutchinson Cancer CenterStarted Aug 1998

Stanford, California, United States • Denver, Colorado, United States • Denver, Colorado, United States +6 more locations

COMPLETEDPhase 3145 miles

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292

RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation.

Fred Hutchinson Cancer CenterStarted Apr 2002

Duarte, California, United States • Stanford, California, United States • Omaha, Nebraska, United States +3 more locations

TERMINATEDPhase 3145 miles

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.

Crohn's Disease

Bristol-Myers Squibb451 participantsStarted Dec 2006

Birmingham, Alabama, United States • Los Angeles, California, United States • Sacramento, California, United States +98 more locations

TERMINATEDPhase 3259 miles

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

NCT00428597

This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received a tablet that looked similar but had no active drug. Neither the patient or the doctor knew whether the patient was receiving sunitinib or placebo. Patients were followed to determine the status and size of their tumors, survival, quality of life and safety of the drug. The study was designed to detect a 50% improvement in median PFS\[Progression Free Survival\] with 90% power and was to enroll 340 subjects. An interim analysis was planned when 130 events had occurred, and the final analysis was to be conducted when 260 events had occurred. Study A6181111 was stopped early during the enrollment period because of a clear and clinically meaningful improvement in efficacy for the sunitinib treatment arm as recommended by the DMC \[Data Monitoring Committee\]. The actual number of subjects enrolled was 171 and the actual number of PFS events recorded was 81 PFS events. The decision to terminate the study was not based on safety concerns related to sunitinib administration.

Carcinoma, Islet CellCarcinoma, Pancreas

Pfizer171 participantsStarted Jun 2007

Aurora, Colorado, United States • Iowa City, Iowa, United States • Worcester, Massachusetts, United States +51 more locations

UNKNOWNPhase 3259 miles

Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation

NCT01217723

This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor. Approximately 50% of the patients enrolled will receive Thymoglobulin® as part of the preparative regimen prior to HPCT. The other 50% of the patients enrolled will receive a standard preparative regimen. Thymoglobulin is known to suppress the types of cells that can cause a transplant complication known as "chronic graft versus host disease (cGVHD)". The goal of this trial is to find out if adding Thymoglobulin to the preparative regimen will result in a decrease in cGVHD.

Hematologic Malignancies

McMaster University198 participantsStarted Apr 2010

Vancouver, British Columbia, Canada • Winnipeg, Manitoba, Canada • Halifax, Nova Scotia, Canada +7 more locations

COMPLETEDPhase 3426 miles

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081

The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).

Benign Prostatic Hyperplasia

Eli Lilly and Company318 participantsStarted Mar 2009

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Anaheim, California, United States +28 more locations

COMPLETEDPhase 3535 miles

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095

This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.

Advanced Stage Parkinson's Disease

Solvay Pharmaceuticals140 participantsStarted Aug 2007

La Jolla, California, United States • San Francisco, California, United States • Fort Lauderdale, Florida, United States +84 more locations

PreviousPage 480 of 503Next

in Portland

Heart Diseasein Portland